Page 169 - 2021_09-Haematologica-web

Rituximab combined with belimumab for adult ITP
References
1. Cines DB, Cuker A, Semple JW. Pathogenesis of immune thrombocytope- nia. Presse Médicale Paris Fr. 1983 2014;43(4 Pt 2):e49-59.
2. Audia S, Mahévas M, Samson M, Godeau B, Bonnotte B. Pathogenesis of immune throm- bocytopenia. Autoimmun Rev. 2017;16(6):620-632.
3.Moulis G, Germain J, Comont T, et al. Newly diagnosed immune thrombocytope- nia adults: Clinical epidemiology, exposure to treatments, and evolution. Results of the CARMEN multicenter prospective cohort. Am J Hematol. 2017;92(6):493-500.
4. Khellaf M, Charles-Nelson A, Fain O, et al. Safety and efficacy of rituximab in adult immune thrombocytopenia: results from a prospective registry including 248 patients. Blood. 2014;124(22):3228-3236.
5. Chugh S, Darvish-Kazem S, Lim W, et al. Rituximab plus standard of care for treat- ment of primary immune thrombocytope- nia: a systematic review and meta-analysis. Lancet Haematol. 2015;2(2):e75-81.
6. Mahévas M, Patin P, Huetz F, et al. B cell depletion in immune thrombocytopenia reveals splenic long-lived plasma cells. J Clin Invest. 2013;123(1):432-442.
7.Audia S, Rossato M, Santegoets K, et al. Splenic TFH expansion participates in B-cell differentiation and antiplatelet-antibody production during immune thrombocytope- nia. Blood. 2014;124(18):2858-2866.
8. Mahévas M, Michel M, Vingert B, et al. Emergence of long-lived autoreactive plas- ma cells in the spleen of primary warm auto-immune hemolytic anemia patients treated with rituximab. J Autoimmun. 2015;62:22-30.
9. Mahévas M, Michel M, Weill J-C, Reynaud C-A. Long-lived plasma cells in autoimmu- nity: lessons from B-cell depleting therapy. Front Immunol. 2013;4:494.
10. Thai L-H, Le Gallou S, Robbins A, et al. BAFF and CD4+T cells are major survival factors for long-lived splenic plasma cells in a B-cell-depletion context. Blood. 2018; 131(14):1545-1555.
11. Mackay F, Schneider P. Cracking the BAFF code. Nat Rev Immunol. 2009;9(7):491-502.
12. Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombo- cytopenic purpura of adults and children: report from an international working group. Blood. 2009;113(11):2386-2393.
13.Grabar S, Groh M, Bahuaud M, et al. Pneumococcal vaccination in patients with systemic lupus erythematosus: A multi- center placebo-controlled randomized double-blind study. Vaccine. 2017;35(37): 4877-4885.
14. Anolik JH, Friedberg JW, Zheng B, et al. B cell reconstitution after rituximab treatment of lymphoma recapitulates B cell ontogeny. Clin Immunol Orlando Fla. 2007;122(2):139- 145.
15. Sanz I, Wei C, Jenks SA, et al. Challenges and opportunities for consistent classifica- tion of human B cell and plasma cell popula- tions. Front Immunol. 2019; 10:2458.
16. Locci M, Havenar-Daughton C, Landais E, et al. Human circulating PD-1+CXCR3- CXCR5+ memory Tfh cells are highly func- tional and correlate with broadly neutraliz- ing HIV antibody responses. Immunity. 2013;39(4):758-769.
17. Lucchini E, Zaja F, Bussel J. Rituximab in the treatment of immune thrombocytopenia: what is the role of this agent in 2019? Haematologica. 2019;104(6):1124-1135.
18. Zaja F, Volpetti S, Chiozzotto M, et al. Long- term follow-up analysis after rituximab sal- vage therapy in adult patients with immune thrombocytopenia. Am J Hematol. 2012;87 (9):886-889.
19. Bussel JB, Lee CS, Seery C, et al. Rituximab and three dexamethasone cycles provide responses similar to splenectomy in women and those with immune thrombocytopenia of less than two years duration. Haematologica. 2014;99(7):1264-1271.
20. Choi PY-I, Roncolato F, Badoux X, Ramanathan S, Ho S-J, Chong BH. A novel triple therapy for ITP using high-dose dex- amethasone, low-dose rituximab, and cyclosporine (TT4). Blood. 2015; 126(4):500- 503.
21. Deshayes S, Khellaf M, Zarour A, et al. Long-term safety and efficacy of rituximab in 248 adults with immune thrombocytope- nia: results at 5years from the French prospective registry ITP-ritux. Am J
Hematol. 2019;94(12):1314-1324.
22. Kraaij T, Kamerling SWA, de Rooij ENM, et al. The NET-effect of combining rituximab with belimumab in severe systemic lupus erythematosus. J Autoimmun. 2018;91:45-
54.
23.Stasi R, Pagano A, Stipa E, Amadori S.
Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood. 2001;98(4):952-957.
24. Cooper N, Stasi R, Cunningham-Rundles S, et al. The efficacy and safety of B-cell deple- tion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocy- topenic purpura. Br J Haematol. 2004;125(2): 232-239.
25. Arnold DM, Heddle NM, Carruthers J, et al. A pilot randomized trial of adjuvant ritux- imab or placebo for nonsplenectomized patients with immune thrombocytopenia. Blood. 2012;119(6):1356-1362.
26. Mei HE, Frölich D, Giesecke C, et al. Steady- state generation of mucosal IgA+ plas- mablasts is not abrogated by B-cell deple- tion therapy with rituximab. Blood. 2010;116(24):5181-5190.
27. Liu Z, Davidson A. BAFF and selection of autoreactive B cells. Trends Immunol. 2011;32(8):388-394.
28. Boneparth A, Woods M, Huang W, Akerman M, Lesser M, Davidson A. The effect of BAFF inhibition on autoreactive B cell selection in murine SLE. Mol Med. 2016;22:173-182.
29. Ueno H, Banchereau J, Vinuesa CG. Pathophysiology of T follicular helper cells in humans and mice. Nat Immunol. 2015; 16(2):142-152.
30. Heit A, Schmitz F, Gerdts S, et al. Vaccination establishes clonal relatives of germinal center T cells in the blood of humans. J Exp Med. 2017;214(7):2139-2152.
31. Coquery CM, Loo WM, Wade NS, et al. BAFF regulates follicular helper t cells and affects their accumulation and interferon-γ production in autoimmunity. Arthritis Rheumatol. 2015;67(3):773-784.
32. Goenka R, Matthews AH, Zhang B, et al. Local BLyS production by T follicular cells mediates retention of high affinity B cells during affinity maturation. J Exp Med. 2014;211(1):45-56.
haematologica | 2021; 106(9)
2457